A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer

"BioTTT001 monotherapy period: BioTTT001 5×10\^7 VP/5×10\^8 VP/5×10\^9 VP/1×10\^10 VP hepatic artery infusion, administered every 2 weeks, for a total of two doses after enrollment.~BioTTT001 in combination with toripalimab and regorafenib period: BioTTT001 5×10\^7 VP/5×10\^8 VP/5×10\^9 VP/1×10\^10 VP hepatic artery infusion, D2 and D16, 4 weeks per cycle， and the dose of BioTTT001 will be determined according to the safety observation results in the monotherapy phase."

BioTTT001 in combination with toripalimab and regorafenib period: toripalimab 80mg intravenous D1 and D15, 4 weeks per cycle.

BioTTT001 in combination with toripalimab and regorafenib period: regorafenib 80 mg oral administration, D1-D21, 4 weeks per cycle.